

Diansheng Zhong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/709949/publications.pdf>

Version: 2024-02-01

30
papers

290
citations

1039880

9
h-index

996849

15
g-index

57
all docs

57
docs citations

57
times ranked

428
citing authors

#	ARTICLE	IF	CITATIONS
1	<sc>CDK4/6</sc> inhibitor palbociclib overcomes acquired resistance to third-generation <sc>EGFR</sc> inhibitor osimertinib in <sc>non-small</sc> cell lung cancer (<sc>NSCLC</sc>). Thoracic Cancer, 2020, 11, 2389-2397.	0.8	36
2	Targeting the <sc>EMT</sc> transcription factor Snail overcomes resistance to osimertinib in <sc>EGFR</sc>-mutant non-small cell lung cancer. Thoracic Cancer, 2021, 12, 1708-1715.	0.8	24
3	2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells. PLoS ONE, 2016, 11, e0168793.	1.1	24
4	Glutamine- β -cyclodextrin for targeted doxorubicin delivery to triple-negative breast cancer tumors <i>via</i> the transporter ASCT2. Journal of Materials Chemistry B, 2019, 7, 5363-5375.	2.9	20
5	Oral fluoropyrimidine <i>versus</i> intravenous 5-fluorouracil for the treatment of advanced gastric and colorectal cancer: Meta-analysis. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 209-225.	1.4	17
6	Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. Clinical Cancer Research, 2020, 26, 3162-3171.	3.2	16
7	An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202). Therapeutic Advances in Medical Oncology, 2020, 12, 175883592090542.	1.4	15
8	EGFR gene-mutation status correlated with therapeutic decision making in lung adenocarcinoma. OncoTargets and Therapy, 2015, 8, 3017.	1.0	12
9	Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer, 2018, 123, 36-43.	0.9	11
10	Concurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance. Thoracic Cancer, 2017, 8, 693-697.	0.8	8
11	High kinesin family member 18A expression correlates with poor prognosis in primary lung adenocarcinoma. Thoracic Cancer, 2019, 10, 1103-1110.	0.8	7
12	Molecular mechanism of acquired drug resistance in the EGFR-TKI resistant cell line HCC827. Thoracic Cancer, 2020, 11, 1129-1138.	0.8	7
13	Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial. Annals of Translational Medicine, 2020, 8, 234-234.	0.7	7
14	Lonafarnib Is a Potential Inhibitor for Neovascularization. PLoS ONE, 2015, 10, e0122830.	1.1	6
15	Liver kinase B1/adenosine monophosphate-activated protein kinase signaling axis induces p21/WAF1 expression in a p53-dependent manner. Oncology Letters, 2018, 16, 1291-1297.	0.8	6
16	Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation. Biochemical and Biophysical Research Communications, 2014, 447, 465-470.	1.0	5
17	EGFR exon 19-deletion aberrantly regulate ERCC1 expression that may partly impaired DNA damage repair ability in non-small cell lung cancer. Thoracic Cancer, 2020, 11, 277-285.	0.8	4
18	Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).. Journal of Clinical Oncology, 2020, 38, 9573-9573.	0.8	4

#	ARTICLE	IF	CITATIONS
19	Case Report: Dramatic Response to Crizotinib in a Patient With Non-Small Cell Lung Cancer Positive for a Novel ARL1-MET Fusion. <i>Frontiers in Oncology</i> , 2022, 12, 804330.	1.3	4
20	Identification of a DNA damage repair gene-related signature for lung squamous cell carcinoma prognosis. <i>Thoracic Cancer</i> , 2022, , .	0.8	4
21	Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analysis. <i>Thoracic Cancer</i> , 2017, 8, 170-180.	0.8	3
22	Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: A retrospective study. <i>Thoracic Cancer</i> , 2021, 12, 1154-1161.	0.8	3
23	Difficult differential diagnosis of bladder pedicled masses about metastasis from non-small cell lung cancer: A case report. <i>Cancer Biology and Therapy</i> , 2021, 22, 106-111.	1.5	3
24	Effect of Betulin on Inflammatory Biomarkers and Oxidative Status of Ova-Induced Murine Asthma. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2020, 39, 213-224.	0.6	3
25	Retrospective study of the efficacy and toxicity of lobaplatin-etoposide chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 226-233.	0.8	2
26	The role of brain metastases in patients with pulmonary adenocarcinoma: a retrospective study. <i>Annals of Palliative Medicine</i> , 2021, 10, 12262-12272.	0.5	2
27	Retrospective study of EGFR mutant lung adenocarcinoma with bone metastatic clinical features. <i>Cancer Reports</i> , 0, , .	0.6	2
28	Apatinib in patients with adenocarcinoma of stomach or gastroesophageal junction: A prospective, multicenter, non-interventional study (Ahead-G202).. <i>Journal of Clinical Oncology</i> , 2018, 36, e16047-e16047.	0.8	1
29	Abstract 374: NGS based profiling of homologous recombination genes to predict response to platinum-based chemotherapy in NSCLC. , 2021, , .		0
30	Abstract 403: The landscape of PD-L1 expression in lung cancer harboring EGFR mutations. , 2021, , .		0